Sydney X. Lu

4.3k total citations
49 papers, 1.1k citations indexed

About

Sydney X. Lu is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, Sydney X. Lu has authored 49 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 21 papers in Molecular Biology and 19 papers in Immunology. Recurrent topics in Sydney X. Lu's work include Multiple Myeloma Research and Treatments (14 papers), T-cell and B-cell Immunology (12 papers) and Immunotherapy and Immune Responses (11 papers). Sydney X. Lu is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), T-cell and B-cell Immunology (12 papers) and Immunotherapy and Immune Responses (11 papers). Sydney X. Lu collaborates with scholars based in United States, Canada and China. Sydney X. Lu's co-authors include Marcel R.M. van den Brink, Adam A. Kochman, Odette M. Smith, Önder Alpdoğan, David Suh, Vanessa M. Hubbard, Theis H. Terwey, Stephanie J. Muriglan, Chen Liu and Robert R. Jenq and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Sydney X. Lu

45 papers receiving 1.1k citations

Peers

Sydney X. Lu

IMMUN

HEMAT

ONCOL

GENET

Jacopo Mariotti Italy

Jeffrey M. Eng United States

Stephanie J. Muriglan United States

Jason Foley United States

Rachelle G. Veenstra United States

Kathleen P. Lowler United States

Thai M. Cao United States

Claudia Cocco Italy

Axel Schulenburg Austria

YC Yang United States

Jacopo Mariotti Italy

Sydney X. Lu

667 ×1.0

IMMUN

562 ×1.0

HEMAT

410 ×1.1

ONCOL

158 ×0.5

110 ×1.3

GENET

Citations per year, relative to Sydney X. Lu Sydney X. Lu (= 1×) peers Jacopo Mariotti

Countries citing papers authored by Sydney X. Lu

Since Specialization

Citations

This map shows the geographic impact of Sydney X. Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sydney X. Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sydney X. Lu more than expected).

Fields of papers citing papers by Sydney X. Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sydney X. Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sydney X. Lu. The network helps show where Sydney X. Lu may publish in the future.

Co-authorship network of co-authors of Sydney X. Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Sydney X. Lu. A scholar is included among the top collaborators of Sydney X. Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sydney X. Lu. Sydney X. Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lu, Sydney X., et al.. (2025). A defective Fe–N ₃ –C single-atom nanozyme for the detection of carcinoembryonic antigen. Nanoscale. 17(46). 26828–26834. 1 indexed citations

Anczuków, Olga, Frédéric H.‐T. Allain, Brittany Angarola, et al.. (2024). Steering research on mRNA splicing in cancer towards clinical translation. Nature reviews. Cancer. 24(12). 887–905. 8 indexed citations

Maclachlan, Kylee, Neha Korde, Sham Mailankody, et al.. (2024). Evaluating serum free light chain ratio as a biomarker in multiple myeloma. Haematologica. 110(2). 493–497.

Bewersdorf, Jan Philipp, Maximilian Stahl, Justin Taylor, et al.. (2023). E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trial. Leukemia. 37(12). 2512–2516. 36 indexed citations

Maclachlan, Kylee, Tina Bagratuni, Efstathios Kastritis, et al.. (2022). Waldenström macroglobulinemia whole genome reveals prolonged germinal center activity and late copy number aberrations. Blood Advances. 7(6). 971–981. 1 indexed citations

Korde, Neha, Malin Hultcrantz, Hani Hassoun, et al.. (2022). Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. Journal of Clinical Oncology. 40(16_suppl). e20005–e20005. 1 indexed citations

Bourcier, Jessie, Simon J. Hogg, Caroline Erickson, et al.. (2022). Attenuation of Graft-Versus-Host-Disease Via Genetic or Pharmacologic Inhibition of the RNA Splicing Factor RBM39. Blood. 140(Supplement 1). 1163–1164.

Shah, Urvi A., Andriy Derkach, Sham Mailankody, et al.. (2021). A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. Blood. 138(Supplement 1). 4759–4759.

Eveillard, Marion, Neha Korde, Benjamin Diamond, et al.. (2021). Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. Clinica Chimica Acta. 516. 136–141. 8 indexed citations

10.

Lu, Sydney X.. (2020). Modern treatments and future directions for newly diagnosed multiple myeloma patients. Best Practice & Research Clinical Haematology. 33(1). 101151–101151. 5 indexed citations

11.

Landgren, Ola, Sydney X. Lu, & Malin Hultcrantz. (2018). MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. Seminars in Hematology. 55(1). 44–50. 21 indexed citations

12.

Jin, Shuiling, Hairui Su, Ngoc Tung Tran, et al.. (2017). Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1. PLoS ONE. 12(5). e0175523–e0175523. 23 indexed citations

13.

Penack, Olaf, Erik Henke, David Suh, et al.. (2010). Inhibition of Neovascularization to Simultaneously Ameliorate Graft-vs-Host Disease and Decrease Tumor Growth. JNCI Journal of the National Cancer Institute. 102(12). 894–908. 48 indexed citations

14.

Penack, Olaf, Odette M. Smith, Amy Cunningham‐Bussel, et al.. (2009). NOD2 regulates hematopoietic cell function during graft-versus-host disease. The Journal of Experimental Medicine. 206(10). 2101–2110. 84 indexed citations

15.

Brink, Marcel R.M. van den, David L. Porter, Sergio Giralt, et al.. (2009). Relapse after Allogeneic Hematopoietic Cell Therapy. Biology of Blood and Marrow Transplantation. 16(1). S138–S145. 70 indexed citations

16.

Lu, Sydney X., et al.. (2008). Antibody response to GD3 ganglioside is independent of NKT cells. Cytotherapy. 10(1). 38–44. 3 indexed citations

17.

Zakrzewski, Johannes L., David Suh, John C. Markley, et al.. (2008). Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nature Biotechnology. 26(4). 453–461. 89 indexed citations

18.

Ramirez‐Montagut, Teresa, Andrew Chow, Daniel Hirschhorn-Cymerman, et al.. (2006). Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity. The Journal of Immunology. 176(11). 6434–6442. 141 indexed citations

19.

Waldman, Elisha, Sydney X. Lu, Vanessa M. Hubbard, et al.. (2005). Absence of β7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 107(4). 1703–1711. 84 indexed citations

20.

Lu, Sydney X., Christopher M. Bositis, Rochelle R. Torgerson, et al.. (1992). Biophysical mechanism of the scavenger site near T cell-presented epitopes. Vaccine. 10(1). 3–7. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact